Use of interim [¹⁸F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy

References

• Haioun C, Itti E, Rahmouni A, . Fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005;106:1376–1381.
   PubMed Web of Science ®Google Scholar
• Lowry L, Hoskin P, Linc D. Developments in the management of Hodgkin's lymphoma. Lancet Oncol 2010;375:786–788.
   Web of Science ®Google Scholar
• Zinzani PL, Gandolfi L, Broccoli A, . Midtreatment (18)F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. Cancer 2011;117:1010–1018.
   PubMed Web of Science ®Google Scholar
• Mikhaeel NG, Hutchings M, Fields PA, . FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005;16:1514–1523.
   PubMed Web of Science ®Google Scholar
• Terasawa T, Lau J, Bardet S, . Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 2009;27:1742–1743.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Schöder H, Teruya-Feldstein J, . Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol 2010;28:1896–1903.
   PubMed Web of Science ®Google Scholar
• Itti E, Juweid ME, Haioun C, . Improvement of early 18F-FDG PET interpretation in diffuse large B-cell lymphoma: importance of the reference background. J Nucl Med 2010;51:1857–1862.
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobsnts SS, Dupont P, . Early restaging positron emission tomography with 18 fluorodeoxyglucose prodicts outcome in patients with aggressive non-Hodgkin lymphoma. Ann Oncol 2002;13:1356–1363.
   PubMed Web of Science ®Google Scholar
• Dupuis J, Itti E, Rahmouni A, . Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. Ann Oncol 2009;20:503–507.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trümper L, Osterborg A, . CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379–391.
   PubMed Web of Science ®Google Scholar
• Halaas JL, Moskowitz CH, Horwitz S, . R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy. Leuk Lymphoma 2005;46:541–547.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 1985;102:596–602.
   PubMed Web of Science ®Google Scholar
• Philip P, Biron P, Maraninchi D, . Role of massive chemotherapy and autologous bone-marrow transplantation in non-Hodgkin's malignant lymphoma. Lancet 1984;1:391.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, . The International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, . The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857–1861.
   PubMed Web of Science ®Google Scholar
• Cox MC, Nofroni I, Ruco L, . Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. Leuk Lymphoma 2008;49:1745–1751.
   PubMed Web of Science ®Google Scholar
• Shimoni A, Zwas ST, Oksman Y, . Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. Exp Hematol 2007;35:534–540.
   PubMed Web of Science ®Google Scholar
• Wiernik PH, Lossos IS, Tuscano JM, . Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4952–4957.
   PubMed Web of Science ®Google Scholar
• Project TIN-HsLPF. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Choi WW, Weisenburger DD, Greiner TC, . A new immunostain algorithm classifies diffuse large B-cell lymphomainto molecular subtypes with high accuracy. Clin Cancer Res 2009;15:5494–5502.
   PubMed Web of Science ®Google Scholar
• Yang DH, Min JJ, Song HC, . Prognostic significance of interim (18)F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. Eur J Cancer 2011;47:1312–1318.
   PubMed Web of Science ®Google Scholar
• Cashen AF, Dehdashti F, Luo J, . 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med 2011;52:386–392.
   PubMed Web of Science ®Google Scholar
• Herrmann K, Wieder HA, Buck AK, . Early response assessment using 3′-deoxy-3′-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res 2007;13:3552–3558.
   PubMed Web of Science ®Google Scholar
• Graf N, Herrmann K, den Hollander J, . Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment. Mol Imaging Biol 2008;10:349–355.
   PubMed Web of Science ®Google Scholar
• Kelsey CR, Beaven AW, Diehl LF, . Radiation therapy in the management of diffuse large B-cell lymphoma:still relevant? Oncology 2010;24:1204–1212.
   PubMed Web of Science ®Google Scholar
• Todeschini G, Secchi S, Morra E, . Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer 2004;90:372–376.
   PubMed Web of Science ®Google Scholar